MX2016002580A - Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. - Google Patents

Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Info

Publication number
MX2016002580A
MX2016002580A MX2016002580A MX2016002580A MX2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A
Authority
MX
Mexico
Prior art keywords
inhibitor
combination
treatment
proliferative diseases
cell proliferative
Prior art date
Application number
MX2016002580A
Other languages
English (en)
Spanish (es)
Inventor
Leslie Harris Jennifer
Li Nanxin
R Smith Timothy
MOSSE Yael
Wood Andrew
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016002580A publication Critical patent/MX2016002580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016002580A 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. MX2016002580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
MX2016002580A true MX2016002580A (es) 2016-10-26

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002580A MX2016002580A (es) 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Country Status (12)

Country Link
US (2) US20160361314A1 (enExample)
EP (1) EP3038652B1 (enExample)
JP (1) JP6479812B2 (enExample)
KR (1) KR20160047521A (enExample)
CN (1) CN106029099A (enExample)
AU (3) AU2014312261A1 (enExample)
BR (1) BR112016004358A8 (enExample)
CA (1) CA2922684A1 (enExample)
ES (1) ES2674361T3 (enExample)
MX (1) MX2016002580A (enExample)
RU (1) RU2016110874A (enExample)
WO (1) WO2015031666A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
SG11202005937QA (en) 2018-01-08 2020-07-29 G1 Therapeutics Inc G1t38 superior dosage regimes
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230019999A1 (en) 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021176349A1 (en) * 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
WO2022063220A1 (en) * 2020-09-25 2022-03-31 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0722383A2 (pt) * 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
EA019094B1 (ru) * 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
EP2429566B1 (en) * 2009-05-13 2016-01-06 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
KR101830455B1 (ko) * 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
HUE025395T2 (en) * 2011-02-02 2016-02-29 Novartis Ag Methods using ALK inhibitors

Also Published As

Publication number Publication date
EP3038652A1 (en) 2016-07-06
RU2016110874A3 (enExample) 2018-06-27
CN106029099A (zh) 2016-10-12
AU2018236813A1 (en) 2018-10-18
BR112016004358A8 (pt) 2020-02-11
JP6479812B2 (ja) 2019-03-06
ES2674361T3 (es) 2018-06-29
US20160361314A1 (en) 2016-12-15
RU2016110874A (ru) 2017-10-04
JP2016529285A (ja) 2016-09-23
AU2017219093A1 (en) 2017-09-14
CA2922684A1 (en) 2015-03-05
EP3038652B1 (en) 2018-03-21
KR20160047521A (ko) 2016-05-02
WO2015031666A1 (en) 2015-03-05
AU2014312261A1 (en) 2016-03-10
US20180318305A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MY192088A (en) Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016502355B1 (en) Pharmaceutical composition
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
HK1211475A1 (en) Combination therapy
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2015DN01156A (enExample)
MX2015017964A (es) Inhibidores de bromodominio.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
IN2013MU03583A (enExample)
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502353A1 (en) Pharmaceutical composition
IN2014MN02236A (enExample)
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX373272B (es) Terapia de combinacion.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.